181 related articles for article (PubMed ID: 37767674)
21. Efficacy of Dapagliflozin According to Geographic Location of Patients With Heart Failure.
Kondo T; Wang X; Yang M; Jhund PS; Claggett BL; Vaduganathan M; Hernandez AF; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Kosiborod MN; Desai AS; Køber L; Ponikowski P; Sabatine MS; Langkilde AM; Petersson M; Zaozerska N; Bachus E; Solomon SD; McMurray JJV
J Am Coll Cardiol; 2023 Sep; 82(10):1014-1026. PubMed ID: 37610398
[TBL] [Abstract][Full Text] [Related]
22. Dapagliflozin in patients with heart failure with mildly reduced and preserved ejection fraction treated with a mineralocorticoid receptor antagonist or sacubitril/valsartan.
Yang M; Butt JH; Kondo T; Jering KS; Docherty KF; Jhund PS; de Boer RA; Claggett BL; Desai AS; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Langkilde AM; Martinez FA; Petersson M; Shah SJ; Vaduganathan M; Wilderäng U; Solomon SD; McMurray JJV
Eur J Heart Fail; 2022 Dec; 24(12):2307-2319. PubMed ID: 36342375
[TBL] [Abstract][Full Text] [Related]
23. Beta-Blocker Use and Heart Failure Outcomes in Mildly Reduced and Preserved Ejection Fraction.
Arnold SV; Silverman DN; Gosch K; Nassif ME; Infeld M; Litwin S; Meyer M; Fendler TJ
JACC Heart Fail; 2023 Aug; 11(8 Pt 1):893-900. PubMed ID: 37140513
[TBL] [Abstract][Full Text] [Related]
24. Dapagliflozin and Apparent Treatment-Resistant Hypertension in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The DELIVER Trial.
Ostrominski JW; Vaduganathan M; Selvaraj S; Claggett BL; Miao ZM; Desai AS; Jhund PS; Kosiborod MN; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Maria Langkilde A; McMurray JJV; Solomon SD
Circulation; 2023 Dec; 148(24):1945-1957. PubMed ID: 37830208
[TBL] [Abstract][Full Text] [Related]
25. Heart Failure, Investigator-Reported Sleep Apnea and Dapagliflozin: A Patient-Level Pooled Meta-Analysis of DAPA-HF and DELIVER.
Butt JH; Jering K; DE Boer RA; Claggett BL; Desai AS; Hernandez AF; Inzucchi SE; Jhund PS; Køber L; Kosiborod MN; Lam CSP; Martinez FA; Ponikowski P; Sabatine MS; Shah SJ; Vaduganathan M; Langkilde AM; Bengtsson O; Petersson M; Sjöstrand M; Wilderäng U; Solomon SD; McMurray JJV
J Card Fail; 2024 Mar; 30(3):436-448. PubMed ID: 38104937
[TBL] [Abstract][Full Text] [Related]
26. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction.
Butt JH; Kondo T; Jhund PS; Comin-Colet J; de Boer RA; Desai AS; Hernandez AF; Inzucchi SE; Janssens SP; Kosiborod MN; Lam CSP; Langkilde AM; Lindholm D; Martinez F; Petersson M; Shah SJ; Thierer J; Vaduganathan M; Verma S; Wilderäng U; Claggett BC; Solomon SD; McMurray JJV
J Am Coll Cardiol; 2022 Nov; 80(18):1705-1717. PubMed ID: 36041668
[TBL] [Abstract][Full Text] [Related]
27. Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
Ostrominski JW; Thierer J; Claggett BL; Miao ZM; Desai AS; Jhund PS; Kosiborod MN; Lam CSP; Inzucchi SE; Martinez FA; de Boer RA; Hernandez AF; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD; Vaduganathan M
JACC Heart Fail; 2023 Nov; 11(11):1491-1503. PubMed ID: 37226448
[TBL] [Abstract][Full Text] [Related]
28. Impact of COVID-19 in patients with heart failure with mildly reduced or preserved ejection fraction enrolled in the DELIVER trial.
Bhatt AS; Kosiborod MN; Claggett BL; Miao ZM; Vaduganathan M; Lam CSP; Hernandez AF; Martinez FA; Inzucchi SE; Shah SJ; de Boer RA; Jhund PS; Desai AS; Fang JC; Han Y; Comin-Colet J; Drożdż J; Vardeny O; Merkely B; Lindholm D; Peterson M; Langkilde AM; McMurray JJV; Solomon SD
Eur J Heart Fail; 2023 Dec; 25(12):2177-2188. PubMed ID: 37771274
[TBL] [Abstract][Full Text] [Related]
29. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
Solomon SD; McMurray JJV; Claggett B; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Jhund PS; Belohlavek J; Chiang CE; Borleffs CJW; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer-Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Saraiva JFK; Tereshchenko SN; Thierer J; Vaduganathan M; Vardeny O; Verma S; Pham VN; Wilderäng U; Zaozerska N; Bachus E; Lindholm D; Petersson M; Langkilde AM;
N Engl J Med; 2022 Sep; 387(12):1089-1098. PubMed ID: 36027570
[TBL] [Abstract][Full Text] [Related]
30. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials.
McMurray JJV; Docherty KF; de Boer RA; Hammarstedt A; Kitzman DW; Kosiborod MN; Maria Langkilde A; Reicher B; Senni M; Shah SJ; Wilderäng U; Verma S; Solomon SD
Circulation; 2024 Mar; 149(11):825-838. PubMed ID: 38059368
[TBL] [Abstract][Full Text] [Related]
31. Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
Solomon SD; Vaduganathan M; Claggett BL; de Boer RA; DeMets D; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Belohlavek J; Chiang CE; Willem Borleffs CJ; Comin-Colet J; Dobreanu D; Drozdz J; Fang JC; Alcocer Gamba MA; Al Habeeb W; Han Y; Cabrera Honorio JW; Janssens SP; Katova T; Kitakaze M; Merkely B; O'Meara E; Kerr Saraiva JF; Tereschenko SN; Thierer J; Vardeny O; Verma S; Vinh PN; Wilderäng U; Zaozerska N; Lindholm D; Petersson M; McMurray JJV
JACC Heart Fail; 2022 Mar; 10(3):184-197. PubMed ID: 35241246
[TBL] [Abstract][Full Text] [Related]
32. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis.
Wang Y; Gao T; Meng C; Li S; Bi L; Geng Y; Zhang P
Eur J Med Res; 2022 Dec; 27(1):314. PubMed ID: 36581880
[TBL] [Abstract][Full Text] [Related]
33. Blood Pressure and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: DELIVER.
Selvaraj S; Vaduganathan M; Claggett BL; Miao ZM; Fang JC; Vardeny O; Desai AS; Shah SJ; Lam CSP; Martinez FA; Inzucchi SE; de Boer RA; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
JACC Heart Fail; 2023 Jan; 11(1):76-89. PubMed ID: 36599553
[TBL] [Abstract][Full Text] [Related]
34. Treatment effects of empagliflozin in hospitalized heart failure patients across the range of left ventricular ejection fraction - Results from the EMPULSE trial.
Tromp J; Kosiborod MN; Angermann CE; Collins SP; Teerlink JR; Ponikowski P; Biegus J; Ferreira JP; Nassif ME; Psotka MA; Brueckmann M; Blatchford JP; Steubl D; Voors AA
Eur J Heart Fail; 2024 Apr; 26(4):963-970. PubMed ID: 38572654
[TBL] [Abstract][Full Text] [Related]
35. Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure.
Vaduganathan M; Claggett BL; Jhund P; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Desai AS; Lindholm D; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
J Am Coll Cardiol; 2022 Nov; 80(19):1775-1784. PubMed ID: 36041669
[TBL] [Abstract][Full Text] [Related]
36. Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial.
Chatur S; Vaduganathan M; Claggett BL; Cunningham JW; Docherty KF; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Inzucchi SE; Kosiborod MN; Lam CSP; Martinez FA; Shah SJ; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
Circulation; 2023 Nov; 148(22):1735-1745. PubMed ID: 37632455
[TBL] [Abstract][Full Text] [Related]
37. Predictors and prognostic implications of left ventricular ejection fraction trajectory improvement in the spectrum of heart failure with reduced and mildly reduced ejection fraction.
Si J; Ding Z; Hu Y; Zhang X; Zhang Y; Cao H; Liu Y
J Cardiol; 2024 Apr; 83(4):250-257. PubMed ID: 37802201
[TBL] [Abstract][Full Text] [Related]
38. Myocardial Strain for Identification of β-Blocker Responders in Heart Failure with Preserved Ejection Fraction.
Park JJ; Choi HM; Hwang IC; Park JB; Park JH; Cho GY
J Am Soc Echocardiogr; 2019 Nov; 32(11):1462-1469.e8. PubMed ID: 31540679
[TBL] [Abstract][Full Text] [Related]
39. Effect of digoxin in patients with heart failure and mid-range (borderline) left ventricular ejection fraction.
Abdul-Rahim AH; Shen L; Rush CJ; Jhund PS; Lees KR; McMurray JJV;
Eur J Heart Fail; 2018 Jul; 20(7):1139-1145. PubMed ID: 29493058
[TBL] [Abstract][Full Text] [Related]
40. Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trial.
Pabon M; Claggett BL; Wang X; Miao ZM; Chatur S; Bhatt AS; Vaduganathan M; Fang JC; Desai AS; Jhund P; Martinez F; de Boer RA; Kosiborod MN; Lam CSP; Shah SJ; Hernandez AF; McMurray JJV; Solomon SD; Vardeny O
Eur J Heart Fail; 2023 Sep; 25(9):1663-1670. PubMed ID: 37632711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
